Recombinetics is involved in animal gene editing and associated technologies for biomedical research, regenerative medicine, and animal agriculture, self-described as a leader in these fields.

Recombinetics

Recombinetics  | 2,157 followers on LinkedIn. Delivering the Next Evolution of Healthcare

 | Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

Led by a team of expert geneticists, genome engineers, and reproductive physiologists, the company is headquartered in St.

Legal and HR Manager at Recombinetics

Nikki Rockstroh, MnCP

Experienced General Counsel & Corporate Secretary | JD, Six Sigma

John Burtis

CFO RCI

Justin Zenanko

Quality Control Supervisor at Recombinetics, Inc.

Ashley Lokensgard

Beta testers wanted: Recombinetics is looking for users of iPSCs to help test our cells and robust growth media. Would your research benefit from the availability of Porcine Pluripotent Stem Cells? At Recombinetics we specialize in gene editing, animal reproduction, and cell manufacturing. With this we have derived and characterized both porcine induced pluripotent and embryonic stem cell lines that are stable for well over 60 passages and counting. We are seeking a handful of beta testers to evaluate how the cells perform in different labs and applications. If this is something you are interested in or would like more information, please contact info@Recombinetics.com or see our website at www.Recombienetics.com #betatest #iPSCs #geneediting #regenativemedicine #stemcells

We’re in Baltimore for ASGCT 2024! Stop by poster #517 on Wednesday, May 8th at 5:30 EST to hear from Jarryd Campbell about our swine reporter models for somatic cell genome editing. We are looking forward to making some new connections and meeting up with old colleagues. #asgct #pigmodel #geneediting

Gene therapy continues to advance healthcare…

Recombinetics is excited to share the work our subsidiary, @Acceligen, has put together. Check out the note in the National Hog Farmer on the work done to generate PRRS resistant pigs. Porcine Respiratory and Reproductive Syndrome (PRRS) is a constant concern for pork production. The scientific information can be found in our paper published in collaboration with Rowland, Robert in the journal of Antiviral Research.

Recombinetics provides gene editing solutions for biomedical research, regenerative medicine, and animal agriculture. The company utilizes its proprietary gene editing platform to develop technologies that impact human health and enhance farm animal value.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 4:38 PM	adbd8a35
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 4:38 PM	3af87514
crunchbase trigger	general	Nov 6, 2024 4:38 PM	d9646b48
crunchbase profile	general
li profile	general	Nov 6, 2024 4:38 PM	5c11a4be
translate crunchbase fundingrounds	general
peers	general	Nov 6, 2024 4:38 PM	40efd545
news basic	general	Nov 6, 2024 4:38 PM	11108036
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

RECO

COM:RECOMBINETICS

Recombinetics